This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial.
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.
EMERYVILLE, Calif. and CHENGDU, China , Feb.
Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. Curing HIV remains the ultimate aspiration for Gilead’s HIV research and development efforts.
and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.
With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drugdevelopers with the tools, insights, and support needed to advance their therapies from concept to clinic. Harnessing emerging technologies The rapid pace of technological innovation is reshaping the landscape of drug discovery.
Drugdevelopment is a complex and highly regulated process. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global counterparts, set rigorous standards to ensure that drugs are safe, effective, and high-quality. Regulatory agencies, such as the U.S.
Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells.
This has opened new opportunities in pharmaceutical drugdevelopment, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.
Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease.
21 participants were vaccinated with HB-101 and 12 received placebo.
NEW YORK and VIENNA, Austria, Nov.
(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.
Although the novel coronavirus is the subject of nearly every media story right now, several years ago it was the Zika virus (ZIKV) gathering a great deal of attention. There are currently no targeted therapeutics for its treatment, nor is there an existing vaccine.
“Tackling the COVID-19 pandemic will require a combination of public health measures, vaccines and therapeutics. “Additionally, as expected, the virus continues to mutate, with the possibility of developing resistance to any one antibody. . Schleifer , M.D., President and Chief Executive Officer of Regeneron.
The year 2022 reflected a transformative path for the drugdevelopment industry. Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drugdevelopers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment.
Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells. “There remains an urgent need for SARS-CoV-2 therapeutic agents that target parts of the virus other than the spike protein that are not as likely to evolve.”
Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 – 5. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.
He joined the Scripps lab to become a structural biologist and a few years later used single-particle cryo-EM to help determine the atomic structure of a key protein on the surface of the human immunodeficiency virus (HIV), the cause of AIDS. Now, Lyumkis has plans to take single-particle cryo-EM to a whole new level—literally.
“The casirivimab and imdevimab antibody cocktail is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D. Yancopoulos, M.D., President and Chief Scientific Officer of Regeneron.
We are pleased vaccines are now approved for the prevention of COVID-19; however, a significant unmet need remains for effective treatments for symptomatic patients. We believe ensifentrine, with its novel mechanism of action, could help to improve COVID-19 patient outcomes.”.
The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drugdevelopment, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.
28, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax.
Dean A.
.” “REGEN-COV2 is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D. REGEN-COV2’s development and manufacturing has been funded in part with federal funds from BARDA under OT number: HHSO100201700020C. Yancopoulos , M.D.,
Experimental DrugDevelopment Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers.
Using drugs that are already on the market was the quickest path forward to evaluate these compounds and possibly help patients now because novel drugdevelopment typically takes years. Scientists needed to evaluate the field of potential drugs-and fast. It is, therefore, a tricky target for drugs.
It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drugdevelopment and commercialization. patients who recovered from COVID-19. .
biomarker discovery), blood typing, autoimmune diseases, food science (including allergy testing), infectious disease surveillance, drug discovery and development as well as vaccinedevelopment. This type of application helps guide the development and optimization of therapeutics.
The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. BeyondSpring – BeyondSpring Inc. Source link.
The Importance of Clinical Research in Medical Advancements Researchers use clinical trials to test a drug’s or other medical treatment’s safety and efficacy. Most modern medicines were developed from clinical trials , and clinical trials remain essential for drugdevelopment.
Upon binding, the antibodies block the spike protein from interacting with ACE2 and thereby prevent virus-induced cell-killing, also known as cytopathic effect. Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model.
This is especially applicable to labs involved in the development of highly sought-after viral therapeutics and vaccines. The time sensitivity of virus research, combined with an increasing complexity of bench tasks, can make it helpful for labs to increase automaticity of experiments.
B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. Structural illustration of B38 antibody (cyan, green) attached to receptor-binding domain of the coronavirus SARS-CoV-2 (magenta). In the U.S.
It wasn’t a silver bullet to the hard problem of drugdevelopment, but it wasn’t too far off either. Another camp believed nucleotides insufficient and that proteins were what mattered, pushing hundreds of millions of dollars into developing high-throughput proteomic sequencing platforms.
Christophe Le Tourneau, MD, Head of the Department of DrugDevelopment and Innovation (D3i) at the Curie Institute, and Principal Investigator of the trial , added: “We have seen very encouraging efficacy results in this hard-to-treat patient population, as well as a satisfying safety profile.
Methods.
Positive August 2024 Eurneffy (epinephrine) Ars Pharmaceuticals Irl Limited Positive August 2024 MResvia (Respiratory Syncytial Virus mRNA vaccine) Moderna Biotech Spain S.L. The information below includes the event type and whether the meeting can be attended by the public (Open) or not (Closed).
PhD, Head of the Department of DrugDevelopment and Innovation (D3i) at the Curie Institute, and a world expert in drugdevelopment and head and neck cancers, is the Principal Investigator of the study. Vaccines for established cancer: overcoming the challenges posed by immune evasion Nat Rev Cancer. References. [1]
A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? In the Nussenzweig lab, the team has spent years searching for broadly neutralizing antibodies against the human immunodeficiency virus (HIV ). Yet many critical questions remain.
For example, reflecting the development of a new standard of care for Covid-19, the guidance stated that “in some situations, use of an active control with a superiority or non-inferiority design may be appropriate.” These topics were covered in the body of the guidance and were addressed in two new appendices.
Yet the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.
Published June 23, 2025 Delilah Alvarado Staff Reporter post share post print email license A micrograph image of influenza A virus. Influenza A virus" [Micrograph]. Study success could open the door to an alternative to seasonal influenza vaccines, which some Wall Street analysts view as a multibillion-dollar sales opportunity.
Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption,” said Kenneth C.
The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.
Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Genetic diversity of HCV is also a significant challenge in HGC vaccinedevelopment. HCV infections are particularly challenging due to their chronicity and quasispecies nature.
. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,
While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drugdevelopment. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus. Despite carrying all of these viruses, bats rarely show symptoms of being sick.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content